Evidence map›Paper›PMID 42696191›Full record

ReviewCurrent atherosclerosis reports2026

Oral Incretin-Based Therapies for Weight Management.

Henry Evan Cheng, Michael Bonafede, Alpana P Shukla

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henry Evan ChengDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine Greenberg Center, 1305 York Avenue, New York, NY, 10021, USA.
Michael BonafedeDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine Greenberg Center, 1305 York Avenue, New York, NY, 10021, USA.
Alpana P ShuklaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine Greenberg Center, 1305 York Avenue, New York, NY, 10021, USA. aps2004@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis paper aims to review the current development of oral incretin-based therapies for treatment of overweight and obesity, and outline the efficacy of upcoming therapeutic candidates as well as their safety profiles. Clinical recommendations are provided regarding the role of oral incretin-based therapies for treatment of overweight and obesity. RECENT

findingsUntil recently, almost all incretin-based therapies have been injectable formulations due to limitations in absorption and bioavailability. Recently, novel techniques have emerged to overcome these barriers, with two agents (oral semaglutide and orforglipron) having obtained FDA approval; multiple other candidates are currently in development. Semaglutide is a peptide GLP-1 receptor agonist and orforglipron is a small-molecule biased GLP-1 receptor agonist approved for treatment of obesity; oral semaglutide is additionally approved for secondary cardiovascular risk reduction. In phase 3 trials, oral semaglutide and orforglipron have demonstrated clinically significant weight loss efficacy of > 10% with an adverse-event profile consistent with the GLP-1 class. Differences in formulations of novel oral agents result in differences in administration guidelines and potential risk of adverse events; with particular concern of drug-induced liver injury observed with first generation small-molecule incretin therapies. Overall, oral incretin-based therapies offer a promising new and potentially more accessible option for patients with overweight or obesity.

Indexed as

Anti-Obesity AgentsIncretinsObesityOverweightWeight LossAdministration, OralGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHumansSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesIncretinsSemaglutideCardiovascular outcomesGlucagon-like-peptide-1 receptor agonistsIncretinsObesityOral

Identifiers

PMID42696191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.